# Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

> **NCT06715891** · PHASE3 · RECRUITING · sponsor: **Materia Medica Holding** · enrollment: 374 (estimated)

## Conditions studied

- Acute Respiratory Viral Infection

## Interventions

- **DRUG:** Raphamin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06715891
- **Lead sponsor:** Materia Medica Holding
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-11
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 374 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06715891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06715891, "Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06715891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*